Holen Sie sich die Stockscreener-App
23.47
6.12%
-1.53
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$25.00
Offen:
$24.765
24-Stunden-Volumen:
2.94M
Relative Volume:
1.60
Marktkapitalisierung:
$2.09B
Einnahmen:
$333.87M
Nettoeinkommen (Verlust:
$-169.00M
KGV:
-11.50
EPS:
-2.04
Netto-Cashflow:
$-157.30M
1W Leistung:
+8.46%
1M Leistung:
+34.81%
6M Leistung:
+21.80%
1J Leistung:
+86.27%
1-Tages-Spanne:
$23.20
$24.82
1-Wochen-Bereich:
$20.84
$28.69
52-Wochen-Spanne:
$12.57
$28.69
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
23.47 | 2.43B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
16,958 Shares in Travere Therapeutics, Inc. $TVTX Bought by Polar Asset Management Partners Inc. - MarketBeat
Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS (NASDAQ:TVTX) - Seeking Alpha
HC Wainwright Reaffirms Buy Rating for Travere Therapeutics (NASDAQ:TVTX) - MarketBeat
TVTX: Stifel Raises Price Target to $25, Maintains Hold Rating | TVTX Stock News - GuruFocus
Travere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 11, 2025 - BioSpace
Jacobs Levy Equity Management Inc. Decreases Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA - sharewise.com
Travere Therapeutics (TVTX) Stock Decline Amid Market Activity - GuruFocus
Wells Fargo Raises Price Target for Travere Therapeutics (TVTX) to $35.00 | TVTX Stock News - GuruFocus
H.C. Wainwright reiterates buy rating on Travere Therapeutics stock By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside - Insider Monkey
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? - Yahoo Finance
FDA Drops Advisory Committee for Travere’s FILSPARI Review - MSN
Analysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) Target Price at $33.43 - MarketBeat
Travere rises as FDA says no AdCom required for Filspari label expansion - MSN
Travere Therapeutics stock hits 52-week high at 25.33 USD - Investing.com India
Top 4% Biotech Hits Three-Year High On An FDA Surprise - Investor's Business Daily
Travere Shares Are Trading Higher Wednesday: What's Going On? - Benzinga
TVTX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus
Travere: No AdCom, No ProblemTargeting Big Revenues With FSGS Approval (NASDAQ:TVTX) - Seeking Alpha
Investors Buy Large Volume of Travere Therapeutics Call Options (NASDAQ:TVTX) - MarketBeat
Jefferies reiterates Buy rating on Travere Therapeutics stock with $35 target - Investing.com Canada
Travere Therapeutics stock hits 52-week high at 25.33 USD By Investing.com - Investing.com Nigeria
Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High - MSN
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for Filspari® in Focused Segmental Glomerulosclerosis - MarketScreener
Travere Therapeutics (TVTX) Rises as FDA Review Progresses Witho - GuruFocus
Travere Therapeutics provides update on FDA advisory committee meeting for Filspari in FSGS - MarketScreener
FDA no longer requires advisory committee for Travere’s FSGS drug - Investing.com
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS - The Globe and Mail
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application - Stocktwits
Trexquant Investment LP Trims Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Bought by Northern Trust Corp - MarketBeat
Adage Capital Partners GP L.L.C. Grows Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
RSI Crosses Above 30 for Travere Therapeutics Inc. — Reversal in Sight2025 Performance Recap & Safe Capital Allocation Plans - beatles.ru
Quant Models Detect Momentum Reversal in Travere Therapeutics Inc.2025 Major Catalysts & Expert Verified Movement Alerts - beatles.ru
Chart based analysis of Travere Therapeutics Inc. trends2025 Geopolitical Influence & Intraday High Probability Alerts - Newser
Travere Therapeutics (NASDAQ:TVTX) Shares Up 5% on Analyst Upgrade - MarketBeat
Identifying reversal signals in Travere Therapeutics Inc.July 2025 Analyst Calls & Advanced Technical Analysis Signals - Newser
Improved Revenues Required Before Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock's 26% Jump Looks Justified - simplywall.st
Is Travere Therapeutics Inc. a good ESG investmentJuly 2025 Setups & Reliable Intraday Trade Alerts - خودرو بانک
Travere Therapeutics Inc. stock trend forecastWeekly Trade Summary & Weekly Hot Stock Watchlists - Newser
How sensitive is Travere Therapeutics Inc. to inflation2025 Analyst Calls & Daily Entry Point Trade Alerts - خودرو بانک
PDT Partners LLC Acquires 62,425 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
What is Travere Therapeutics Inc.’s book value per share2025 Market Overview & Smart Swing Trading Techniques - خودرو بانک
Can Travere Therapeutics Inc. lead its sector in growthPortfolio Performance Report & Long-Term Capital Growth Ideas - خودرو بانک
Can Travere Therapeutics Inc. rally from current levels2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Does Travere Therapeutics Inc. stock have upside surprise potentialMarket Growth Review & Fast Entry High Yield Tips - خودرو بانک
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):